About Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:ANIK
- CUSIP: 03525510
- Web: www.anikatherapeutics.com
- Market Cap: $876.7 million
- Outstanding Shares: 14,658,000
- 50 Day Moving Avg: $57.54
- 200 Day Moving Avg: $50.30
- 52 Week Range: $41.38 - $60.27
Sales & Book Value:
- Trailing P/E Ratio: 26.57
- Foreward P/E Ratio: 35.39
- P/E Growth: 2.72
- Annual Revenue: $111.36 million
- Price / Sales: 7.87
- Book Value: $16.66 per share
- Price / Book: 3.59
- EBITDA: $56.02 million
- Net Margins: 30.44%
- Return on Equity: 14.88%
- Return on Assets: 13.78%
- Current Ratio: 14.35%
- Quick Ratio: 13.04%
- Average Volume: 89,612 shs.
- Beta: 1.66
- Short Ratio: 14.7
Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc. (NASDAQ:ANIK) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.32. The business had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The company's revenue was up 25.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 EPS. View Anika Therapeutics' Earnings History.
When will Anika Therapeutics make its next earnings announcement?
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Synlogic (SYBX), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Vericel Corp (VCEL), MediWound (MDWD), KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS) and Opiant Pharmaceuticals (OPNT).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Joseph G. Darling, President
- Charles H. Sherwood Ph.D., Chief Executive Officer, Director
- Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
- Dana M. Alexander, Chief Operating Officer
- Edward Ahn Ph.D., Chief Technology and Strategy Officer
- Richard Hague, Chief Commercial Officer
- Joseph Lyon Bower Ph.D., Lead Independent Director
- Raymond J. Land, Independent Director
- Glenn R. Larsen Ph.D., Independent Director
- Jeffrey S. Thompson, Independent Director
Who owns Anika Therapeutics stock?
Anika Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
(11.49%), Fisher Asset Management LLC (0.72%) and Eqis Capital Management Inc. (0.28%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.
Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?
How do I buy Anika Therapeutics stock?
Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Anika Therapeutics stock can currently be purchased for approximately $59.81.
Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/27/2016||Northland Securities||Downgrade||Outperform -> Market Perform||N/A|
|2/26/2016||Barrington Research||Boost Price Target||Outperform||$45.00 -> $49.00||N/A|
Earnings History for Anika Therapeutics (NASDAQ:ANIK)Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017||Q2 2017||$0.44||$0.76||$27.20 million||$33.50 million||View||N/A|
|5/3/2017||Q1 2017||$0.38||$0.37||$23.89 million||$23.39 million||View||Listen|
|2/15/2017||Q416||$0.53||$0.54||$27.84 million||$28.70 million||View||N/A|
|10/26/2016||Q316||$0.47||$0.59||$26.60 million||$25.79 million||View||Listen|
|7/27/2016||Q216||$0.44||$0.57||$24.75 million||$26.60 million||View||Listen|
|4/27/2016||Q116||$0.28||$0.45||$19.26 million||$22.30 million||View||Listen|
|2/24/2016||Q415||$0.60||$0.72||$28.19 million||$25.60 million||View||Listen|
|10/28/2015||Q315||$0.34||$0.55||$22.36 million||$23.70 million||View||Listen|
|7/29/2015||Q215||$0.34||$0.51||$21.65 million||$22.90 million||View||Listen|
|4/28/2015||Q115||$0.21||$0.23||$16.20 million||$15.50 million||View||Listen|
|2/25/2015||Q414||$0.48||$0.51||$24.60 million||$23.30 million||View||Listen|
|10/29/2014||Q314||$0.33||$0.40||$20.33 million||$22.10 million||View||Listen|
|7/30/2014||Q214||$0.57||$0.60||$28.20 million||$26.27 million||View||Listen|
|4/29/2014||Q114||$0.25||$0.97||$16.03 million||$34.00 million||View||N/A|
|2/26/2014||Q413||$0.42||$0.44||$21.91 million||$21.30 million||View||Listen|
|10/31/2013||Q313||$0.14||$0.33||$16.96 million||$17.80 million||View||Listen|
|7/31/2013||Q2 2013||$0.25||$0.40||$17.09 million||$20.80 million||View||Listen|
Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 6.57%Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership Percentage: 84.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/16/2017||Charles H Sherwood||CEO||Sell||3,293||$60.04||$197,711.72|| |
|10/13/2017||Charles H Sherwood||CEO||Sell||7,124||$60.08||$428,009.92|| |
|7/27/2017||Charles H Sherwood||CEO||Sell||63,799||$50.79||$3,240,351.21|| |
|7/5/2017||Charles H Sherwood||CEO||Sell||14,201||$50.03||$710,476.03|| |
|5/22/2017||Jeffery S Thompson||Director||Sell||10,725||$47.39||$508,257.75|| |
|11/9/2016||Joseph I Bower||Director||Sell||540||$43.39||$23,430.60|| |
|2/25/2016||Raymond J Land||Director||Sell||2,695||$43.62||$117,555.90|| |
|2/27/2015||Raymond J Land||Director||Sell||4,621||$39.49||$182,483.29|| |
|5/1/2014||Charles H Sherwood||CEO||Sell||83,780||$44.32||$3,713,129.60|| |
|2/28/2014||Charles H Sherwood||CEO||Sell||200,000||$41.70||$8,340,000.00|| |
|8/22/2013||John C Moran||Director||Sell||5,000||$24.35||$121,750.00|| |
|8/8/2013||Steve E Wheeler||Director||Sell||26,984||$23.61||$637,092.24|| |
|8/7/2013||Steve E Wheeler||Director||Sell||11,016||$27.01||$297,542.16|| |
|8/6/2013||Farmaceutici S.P.A. Fidia||Major Shareholder||Sell||1,270,000||$24.52||$31,140,400.00|| |
|7/15/2013||Charles H Sherwood||CEO||Sell||75,000||$20.11||$1,508,250.00|| |
|7/9/2013||Charles H Sherwood||CEO||Sell||49,185||$18.06||$888,281.10|| |
|7/5/2013||Charles H Sherwood||CEO||Sell||34,662||$18.01||$624,262.62|| |
|6/19/2013||Charles H Sherwood||CEO||Sell||1,847||$18.00||$33,246.00|| |
Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
Loading headlines, please wait.
Anika Therapeutics (ANIK) Chart for Monday, October, 23, 2017